I-Lab Angels

About

Portfolio · 2

ViAqua Therapeutics

Oral Delivery Platform for Preventing Aquaculture Diseases

1 round $8.3M committed Latest: 2023-09

Quris-AI

AI-based Drug Development Platform

1 round $9.0M committed Latest: 2022-12

Investment activity

Q&A

What is I-Lab Angels' primary investment thesis?

I-Lab Angels supports the growth of Israel’s major research universities and institutions by investing in their entrepreneurial students, professors, and alumni to achieve financial returns for investors, while sharing a portion with the institutions.

When was I-Lab Angels founded?

I-Lab Angels was founded in 2021.

Who are the founders of I-Lab Angels?

The founders of I-Lab Angels are David Rosenblatt, Matt Golub, and Danielle Capalino.

What investment stages does I-Lab Angels focus on?

I-Lab Angels focuses on Pre-Seed, Seed, and A Round investment stages.

Can you name some of I-Lab Angels' portfolio companies?

I-Lab Angels has invested in Quris-AI, an AI-based drug development platform, and ViAqua Therapeutics, an oral delivery platform for preventing aquaculture diseases.

What sectors has I-Lab Angels invested in?

I-Lab Angels has invested in the Agriculture & Food Technologies and Health Tech & Life Sciences sectors.

What was I-Lab Angels' most recent investment activity?

I-Lab Angels made an investment in September 2023, following an investment in December 2022.

What is the typical investment range for I-Lab Angels?

I-Lab Angels typically invests between $100K and $500K.